Iveric Bio

Iveric Bio

World Rank (Jan-05-2024)
2,731
World Rank (Jul-30-2023)
2,731
Market Cap (Jul-30-2023)
5.510 Billion USD
World Rank (Jan-07-2022)
7,176
Market Cap (Jan-07-2022)
1.605 Billion USD
World Rank (Jan-01-2021)
10,121
Market Cap (Jan-01-2021)
0.621 Billion USD
Company Rank in Country in 2023
Rank in USA in July-2023 is 925
Headquarters Country
USA
Employee Count
163
Employee Count as of Date
As on 2022
Headquarters City/State
New York
World Region
Americas
World Subregion
Northern America
Annual Operating Income in USD
-189 Million USD
Annual Net Income in USD
-185 Million USD
Annual Results for Period Ending
Dec-2022 ending period
Total Assets in USD
666 Million USD
Total Liabilities in USD
132 Million USD
Total Equity in USD
534 Million USD
Balance Sheet for Period Ending
Dec-2022 ending period
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
IVERIC BIO
Yahoo
Yahoo @ Frankfurt
Company Profile

Iveric Bio is an Innovative Biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs. Iveric Bio 163 employees as on 2022. The headquarters is in USA.

Astellas Pharma Inc. (TSE: 4503) has completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE) on July 11, 2023 and the acquisition price of the same was 5.9 billion USD.

Annual Results Summary

IVERIC BIO - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-20210-114 (Loss)-114 (Loss)
Dec-20200-88 (Loss)-84 (Loss)
Dec-20190-61 (Loss)-58 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2021 was 389 Million USD.

Total Liabilities as on Dec-2021 was 28 Million USD.

Total Equity as on Dec-2021 was 360 Million USD.

Founded Year
2007
Stock Exchange
Frankfurt

Share